P J Easterbrook
Overview
Explore the profile of P J Easterbrook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
2019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lanini S, Easterbrook P, Zumla A, Ippolito G
Clin Microbiol Infect
. 2016 Aug;
22(10):833-838.
PMID: 27521803
It is estimated that globally there are approximately 100 million persons with serological evidence of current or past HCV infection, and that HCV causes about 700 000 deaths each year....
2.
Basnayake S, Easterbrook P
J Viral Hepat
. 2016 Mar;
23(7):545-59.
PMID: 27028545
To evaluate the extent of heterogeneity in global estimates of chronic hepatitis B (HBV) and C (HCV) cited in the published literature, we undertook a systematic review of the published...
3.
Gerver S, Easterbrook P, Anderson M, Solarin I, Elam G, Fenton K, et al.
Int J STD AIDS
. 2011 Mar;
22(2):85-90.
PMID: 21427429
We compared sociodemographic characteristics, sexual risk behaviours and sexual health experiences of 266 heterosexual black Caribbeans recruited at a London sexual health clinic between September 2005 and January 2006 with...
4.
Easterbrook P, Phillips A, Hill T, Matthias R, Fisher M, Gazzard B, et al.
HIV Med
. 2008 Jan;
9(1):47-56.
PMID: 18199172
Background: We describe the patterns of antiretroviral drug use at treatment initiation from 1996 to 2005 in a large UK multicentre cohort. Methods: We examined trends over time and across...
5.
Ratnam I, Chiu C, Kandala N, Easterbrook P
Clin Infect Dis
. 2006 Jan;
42(3):418-27.
PMID: 16392092
Background: It is estimated that 10%-25% of patients who start highly active antiretroviral therapy (HAART) experience immune reconstitution inflammatory syndrome (IRIS). Our objective was to determine the incidence, clinical spectrum,...
6.
Mohsen A, Murad S, Easterbrook P
HIV Med
. 2005 May;
6(3):206-15.
PMID: 15876288
Objectives: There is limited information on the prevalence of and risk factors for hepatitis C virus (HCV) infection among HIV-1-infected patients in the UK. Our objective was to determine the...
7.
Boyd A, Murad S, OShea S, de Ruiter A, Watson C, Easterbrook P
HIV Med
. 2005 Apr;
6(2):59-65.
PMID: 15807711
Objectives: To establish whether there were ethnic differences in demographic characteristics, the stage at HIV diagnosis and reasons for and location of HIV testing between 1998 and 2000 in a...
8.
Boaz M, Waters A, Murad S, Easterbrook P, DSousa E, van Wheeley C, et al.
Clin Exp Immunol
. 2003 Nov;
134(3):454-63.
PMID: 14632751
Characterization of immune responses to immunodominant CD4 epitopes in HIV-1 that are associated with control of HIV infection could be used to strengthen the efficacy of polyepitope HIV vaccines. We...
9.
Easterbrook P, Waters A, Murad S, Ives N, Taylor C, King D, et al.
HIV Med
. 2003 Oct;
4(4):321-4.
PMID: 14525543
We investigated risk factors for hypersensitivity reactions (HSR) to abacavir in a case-control study. In a multivariate analysis, white race [odds ratio (OR), 5.16; 95% confidence interval (CI), 1.16-22.97] and...
10.
Mohsen A, Easterbrook P, Taylor C, Portmann B, Kulasegaram R, Murad S, et al.
Gut
. 2003 Jun;
52(7):1035-40.
PMID: 12801963
Objectives: To compare the rate of hepatic fibrosis progression in hepatitis C virus (HCV) infected and human immunodeficiency virus (HIV)-HCV coinfected patients, and to identify factors that may influence fibrosis...